Search citation statements
Paper Sections
Citation Types
Year Published
Publication Types
Relationship
Authors
Journals
The study is relevant due to an increase of oncological diseases and its complications from tumor growth or treatment. Research purpose : to study in an experiment the formation of pathomorphological changes in kidney tissue, taking into account the development of the tumor process and cytostatic therapy. Research objectives : to study morphological changes in the kidneys caused by the tumor process in an animal experiment; to study the effect of methotrexate on the dynamics of pathomorphological changes in the kidneys; to identify of the severity of pathomorphological changes in experimental groups. Materials and methods . We conduct the study on Balb/c mice according to the recommendations set out by the Ministry of Health of the USSR no. 755 and the Helsinki Declaration. Euthanasia was performed by administration of sodium thiopental. The control group was represented by mice without formed tumors. Experimental groups were formed from animals with tumors. Pathomorphological changes in the kidneys were studied both without the administration of methotrexate and with the use of methotrexate. Cytostatic was administered in a dosage of 0.2 mg. Pathomorphological studies of tumors and kidneys were carried out according to the standard histological technique. Results . In experimental groups of animals with a tumor process, nonspecific pathomorphological changes prevailed in the form of irreversible necrobiotic and microcirculatory changes in both cortical and cerebral sections of nephrons, while fibroplastic and microcirculatory changes prevailed when methotrexate was administered. Conclusion . The severity of pathomorphological changes in the kidneys depended on the presence of a tumor process and the effects of methotrexate.
The study is relevant due to an increase of oncological diseases and its complications from tumor growth or treatment. Research purpose : to study in an experiment the formation of pathomorphological changes in kidney tissue, taking into account the development of the tumor process and cytostatic therapy. Research objectives : to study morphological changes in the kidneys caused by the tumor process in an animal experiment; to study the effect of methotrexate on the dynamics of pathomorphological changes in the kidneys; to identify of the severity of pathomorphological changes in experimental groups. Materials and methods . We conduct the study on Balb/c mice according to the recommendations set out by the Ministry of Health of the USSR no. 755 and the Helsinki Declaration. Euthanasia was performed by administration of sodium thiopental. The control group was represented by mice without formed tumors. Experimental groups were formed from animals with tumors. Pathomorphological changes in the kidneys were studied both without the administration of methotrexate and with the use of methotrexate. Cytostatic was administered in a dosage of 0.2 mg. Pathomorphological studies of tumors and kidneys were carried out according to the standard histological technique. Results . In experimental groups of animals with a tumor process, nonspecific pathomorphological changes prevailed in the form of irreversible necrobiotic and microcirculatory changes in both cortical and cerebral sections of nephrons, while fibroplastic and microcirculatory changes prevailed when methotrexate was administered. Conclusion . The severity of pathomorphological changes in the kidneys depended on the presence of a tumor process and the effects of methotrexate.
В статье описаны случаи дебюта острого лимфобластного лейкоза, имеющие маску почечной патологии у детей. Особенностью представленных случаев является ранняя манифестация заболевания на фоне отсутствия классических мар-керов онкологических заболеваний. Верифицировать диагноз удалось только на основании иммуногистохимического исследования. Данная работа может быть актуальна для педиатров, детских онкологов и гематологов, детских нефрологов.
The review addresses the problem of kidney lesions in patients with cardiovascular and oncological diseases. In the context of the current spread of cardiovascular and oncological pathologies, a growing number of patients reveal comorbid and/or polymorbid renal dysfunctions. In confluence with cardiovascular disorders, kidney lesions are manifested in various types of the cardiorenal syndrome. In current knowledge, the heart and kidneys are highly interdependent and interact across several interfaces in a complex feedback system. The kidneys can both play a target role and back-influence cardiac functions and pathology. Evidently, the development of acute kidney lesions and / or chronic renal dysfunctions worsens the prognosis of the primary disease and elevates risks of developing acute cardiovascular disorders. Combined cardiovascular and oncological pathologies are nowadays more common. Numerous patients with malignant neoplasms develop renal pathologies due to tumour infiltration or exposure to tumour metabolites, as well as indirectly through the nephrotoxic effect of antitumour chemotherapy and/or radiation therapy. Many studies show that acute kidney lesions and/or chronic renal disorders contribute independently to the severity of cancer and mortality rate. In recent decades, the level of serum creatinine is used as a marker of acute kidney damage, which although harbours inherent weaknesses of being responsive to a spectrum of renal and extra-renal factors and having a delay of 48–72 h of elevation in the blood after exposure to the trigging factor. In this respect, the development of novel kidney-specific lesion biomarkers continues. Among such candidate agents is the kidney injury molecule KIM-1.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.